Silence Therapeutics plc (SLNCF)

Market Cap	335.23M
Revenue (ttm)	21.77M
Net Income (ttm)	-78.89M
Shares Out	n/a
EPS (ttm)	-1.79
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	2.250
Previous Close	2.250
Day's Range	2.250 - 2.250
52-Week Range	0.910 - 14.750
Beta	1.28
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 13, 2025

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company’s mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1994
• Employees: 109
• Stock Exchange: OTCMKTS
• Ticker Symbol: SLNCF

Financial Performance

In 2023, Silence Therapeutics's revenue was 25.38 million, an increase of 44.99% compared to the previous year's 17.50 million. Losses were -43.27 million, 6.86% more than in 2022.

Financial numbers in GBP